Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes

As a prognostic biomarker for progression of diabetic nephropathy, albuminuria fails in terms of sensitivity and specificity. Better urinary or plasma biomarkers are needed that can predict which diabetic patients are at highest risk for progression. Bhensdadia et al. report proteomic investigations that identified urinary haptoglobin as a potential prognostic biomarker for progressive diabetic nephropathy. Although as a single marker urinary haptoglobin adds little to albuminuria, together the two appear to provide better diagnostic accuracy than albuminuria alone. Excess adiposity is the most important risk factor for the development of insulin resistance and type 2 diabetes (1). However, mechanisms whereby body fat induces insulin resistance in distant tissues are not well understood. Recent evidence indicates that obesity may be an inflammatory markers.
  • Prognostic biomarkers
  • Diabetic nephropathy biomarkers
  • Diabetes: Clinical trials and new biomarkers under development
  • Pharmacotherapy in treatment of diabetes
  • Molecular markers for both metabolic syndrome and hypoglycemia responses
  • Inflammatory markers: Type 2 diabetes
  • New drug treatments and devices for diabetes: current research

Related Conference of Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes

July 17-18, 2017

18th European Diabetes Congress

Lisbon, Portugal
July 20-22, 2017

19thAsia Pacific Diabetes Conference

Melbourne, Australia
July 24-26,2017

10th Diabetologists Conference

Vancouver, Canada
September 20-22, 2017

International Conference on Diabetes and Diabetic Nursing Care

Charlotte, North Carolina, USA
October 30- November 1, 2017

9th Annual Congress on Endocrine Disorders and Therapies


(10 Plenary Forums - 1 Event)
Chicago, Illinois, USA
December 04-05, 2017

25th Global Diabetes Summit and Medicare Expo

Dubai, UAE
October 30-November 01, 2017

10th International Conference on Endocrinology

Chicago, Illinois, USA
February 12-13,2018

7th European Diabetes and Endocrinology Congress

Munich, Germany

Advancement of New Drug/Biomarker Discovery for Treatment of Diabetes Conference Speakers